Does low ferritin weaken the classic inflammatory iron sequestration explanation?

Iron homeostasis is tightly regulated, but inflammatory states disrupt this balance, complicating the clinical interpretation of a patient's iron status.

Mechanistic pathways of inflammatory sequestration

• Cytokine-driven hepcidin synthesis: Systemic inflammatory cytokines, primarily interleukin-6 (IL-6), bind to hepatocyte receptors and activate the intracellular JAK-STAT3 signaling pathway. Phosphorylated STAT3 translocates to the nucleus, binding the promoter of the HAMP gene to upregulate hepcidin expression.
• Ferroportin degradation: Elevated circulating hepcidin directly binds to ferroportin—the sole cellular iron exporter—on macrophages, hepatocytes, and enterocytes. This binding induces conformational changes, ubiquitination of lysine residues, endocytosis, and subsequent lysosomal degradation of the exporter.
• Intracellular trapping: Without functional surface ferroportin, iron absorbed from the diet or recycled from senescent red blood cells is trapped inside cells. This cellular retention causes a marked reduction in circulating available serum iron while intracellular ferritin levels rise.

Diagnostic implications of low ferritin

• Absolute vs. functional deficiency: In the classic model of inflammatory iron sequestration (anemia of chronic disease), ferritin acts as an acute-phase reactant and is typically normal or elevated (often >100 µg/L) despite low circulating serum iron.
• Undermining the classic model: A low serum ferritin level—typically defined as <30–100 µg/L in the presence of active inflammation—directly contradicts pure functional sequestration. It demonstrates that total body iron stores are exhausted, as the stimulus of inflammation is insufficient to raise ferritin when absolute iron deficiency is present.

Bottom line

• While inflammation typically drives hepcidin-mediated iron trapping to raise ferritin, a low ferritin level (<30–100 µg/L) undermines the classic inflammatory sequestration model, establishing absolute iron deficiency as the primary clinical driver.